Introduction {#S1}
============

The incidence of pulmonary infections caused by non-tuberculous mycobacteria (NTM) has increased dramatically worldwide in recent years ([@B8]; [@B22]; [@B15]). Among them, *Mycobacterium abscessus* (*M. abscessus*) infections are the most difficult to manage ([@B25]; [@B3]). *M. abscessus* infections, which are even refractory to combined, long-term antibiotic therapy, often result in mortality.

*Mycobacterium abscessus* treatment is challenging, albeit effective treatment options are evolving. In 2007, the American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) introduced a clarithromycin-based multidrug therapy with amikacin plus cefoxitin or imipenem administered parenterally ([@B4]). In 2017, the British Thoracic Society guidelines recommended a revision in antibiotic therapy that consisted of intravenous amikacin, tigecycline, and imipenem with a macrolide, e.g., clarithromycin, for the initial treatment phase ([@B7]). This was followed by a continuation phase composed of nebulized amikacin and a macrolide in combination with additional oral antibiotics. It was further recommended that selection of a specific agent should consider the antibiotic susceptibility of the isolate and the antibiotic tolerance of the patient.

Patients with pulmonary disease due to *M. abscessus* infection require long-term treatment with multiple antibiotics. Little is known about the impact of each antibiotic on treatment outcomes. Recently, the NTM International Network released a consensus statement defining the treatment outcomes of NTM pulmonary disease, allowing for a better evaluation of the efficacy of each antibiotic used in clinical studies ([@B31]). Using these criteria, [@B13] conducted an excellent meta-analysis of 14 studies with detailed individual patient data. Patients treated with drug combinations that included azithromycin, amikacin, or imipenem exhibited better outcomes, emphasizing the import of different therapeutic approaches. However, two important antibiotics specifically recommended in the 2017 British Thoracic Society guidelines, i.e., linezolid and tigecycline, were not used or were administered in very few cases. Moreover, despite identifying the antibiotics most effective, the adverse effects of these antibiotics were not considered.

We previously reported a series of studies demonstrating the antibiotic susceptibility of clinical *M. abscessus* isolates and the treatment outcomes of patients diagnosed with *M. abscessus* pulmonary disease ([@B19], [@B21]; [@B5]; [@B33]). A number of cases accumulated during the course of these studies dealt with the long-term treatment with antibiotics, including linezolid and tigecycline; the adverse effects of antibiotic treatment were well documented. The retrospective analysis reported herein was undertaken to evaluate the efficacy and adverse effect of a variety of antibiotics used to treat *M. abscessus* pulmonary disease. The results of this analysis should facilitate therapeutic choices in clinical practice.

Materials and Methods {#S2}
=====================

Study Population {#S2.SS1}
----------------

A retrospective review was conducted of the medical records of all patients entering Shanghai Pulmonary Hospital between January 2012 and December 2017 with *M. abscessus* lung disease. Participating patients were followed-up on a regular basis; sputum culture and chest CT examination were performed once a month and once every 3 months, respectively. The inclusion criteria were: (1) age \> 16 years; (2) having undergone initial diagnosis and treatment at the Shanghai Pulmonary Hospital in accordance with the 2007 ATS/IDSA Guidelines or the 2017 British Thoracic Society Guidelines; and (3) follow-up period lasting \>12 months. Exclusion criteria were: (1) age \< 16 years; (2) co-infection with active tuberculosis or another NTM; (3) refusal to sign informed consent form; and (4) AIDS. Notably, patients with cystic fibrosis were never found and are essentially non-existent in Asia. A detailed, patient enrollment flow chart is shown in [Figure 1](#F1){ref-type="fig"}. This study was approved by the Ethics Committees of Shanghai Pulmonary Hospital and Tongji University School of Medicine, ethics number K17-150. All participants signed informed consent forms before enrollment.

![Flow diagram of the study. Two hundred forty-four pulmonary disease patients, who conformed to the inclusion criteria, were enrolled. One hundred eighty-five patients were infected with *M. abscessus* subsp. *abscessus*; 59 patients were infected with *M. abscessus* subsp. *massiliense*.](fmicb-10-01977-g001){#F1}

Collection, Identification, and Preservation of Bacteria {#S2.SS2}
--------------------------------------------------------

All clinical *M. abscessus* isolates used in this study were preserved in the Clinical Microbiology Laboratory of Shanghai Pulmonary Hospital. Shanghai Pulmonary Hospital is one of the designated treatment centers for tuberculosis and NTM in China, attracting NTM cases nationwide. *M. abscessus* isolates were obtained from sputum and bronchoalveolar lavage fluid. The detailed process of *M. abscessus* identification was described previously by us using *rpoB*, *erm*(41), and *PRA-hsp65* genes to identify and differentiate *abscessus*, *massiliense*, and *bolletii* subspecies ([@B5]). *M. abscessus* subsp. *bolletii* is extremely rare and, therefore, was excluded. Identified isolates, stored at −80°C, were recovered for microbiology and molecular biology studies.

Genotype Analysis {#S2.SS3}
-----------------

Genomic information of *rpoB*, *erm*(41), and *PRA-hsp65* genes for 182 isolates was obtained by whole genome sequencing, which was available at DDBJ/ENA/GenBank under the BioProject [PRJNA448987](PRJNA448987), [PRJNA398137](PRJNA398137), and [PRJNA488058](PRJNA488058). The genotype of the remaining isolates was determined by PCR and sequencing the *rpoB*, *erm*(41), and *PRA-hsp65* genes.

Treatment Regimen {#S2.SS4}
-----------------

All patients were treated with antibiotics recommended by the ATS/IDSA or the British Thoracic Society guidelines ([@B4]; [@B7]). Clarithromycin, azithromycin, amikacin, tigecycline, linezolid, imipenem, meropenem, cefoxitin, ciprofloxacin, moxifloxacin, doxycycline, minocycline, and levofloxacin (among the most common antibiotics used to treat *M. abscessus* infections) were included in the analysis. These antibiotics were selected based upon: drug susceptibility, adverse side effects, medical history, economic considerations, and the ease with which the regimens could be modified during the course of treatment.

Treatment Efficacy and Adverse Drug Effects {#S2.SS5}
-------------------------------------------

Treatment outcomes were defined in accordance with the NTM International Network consensus statement ([@B31]); a microbiological cure was considered successful treatment. Since all patients enrolled in the current study were simultaneously or sequentially treated with more than one drug, analysis of the direct response to a single drug was impossible. Rather, the efficacy of individual drugs was assessed based upon a comparison of the frequency of drug usage in successfully versus unsuccessfully treated patients ([@B13]). Evaluation of chest images and symptoms was determined by the treating physician. Adverse drug effects and the drugs responsible were identified by referring to the medical records and confirmed by the diminution or elimination of symptoms following drug cessation.

Statistical Analysis {#S2.SS6}
--------------------

Statistical analysis was conducted using SPSS version 20 (IBM Corporation, Chicago, IL, United States). Group comparisons for continuous data were performed using Mann--Whitney *U*-test. Group comparisons of proportions were made using Pearson's chi-squared test or Fisher's exact test. Multivariable logistic regression was used to confirm the association of specific drug use with treatment success; symptomatic and radiographic improvement; and adjusting for age, sex, BMI, and radiographic features. Statistical significance was set at a two-sided *p*-value of \<0.05.

Results {#S3}
=======

Patient Characteristics {#S3.SS1}
-----------------------

Two hundred and forty-four patients who conformed to the recruitment criteria were enrolled. Among them, 75.8% of the patients were infected with *M. abscessus* subsp. *abscessus*; 24.2% were infected with *M. abscessus* subsp. *massiliense* ([Table 1](#T1){ref-type="table"}). Patients experiencing *M. abscessus* pulmonary disease were 73.0% female and had relatively low body mass indices. Most of the patients had comorbidities consisting of prior TB/NTM infection or bronchiectasis. The main symptoms were cough and sputum production. The proportion of pulmonary disease patients infected with *M. abscessus* subsp. *abscessus* exhibited more fibrocavitary and less nodular bronchiectasis in chest images relative to patients infected with *M. abscessus* subsp. *massiliense*.

###### 

Baseline patient characteristics^a^.

                                  **Total (*n* = 244)**   ***M. abscessus* subsp. *abscessus* pulmonary disease (*n* = 185)**   ***M. abscessus* subsp. *massiliense* pulmonary disease (*n* = 59)**   ***P*-value**
  ------------------------------- ----------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------
  Median age (years)              56.0(49.0,65.8)^b^      56(49.0,66.0)^b^                                                      54.0(48.0,63.0)^b^                                                     0.207
  Sex, male                       66(27.0)                53(28.6)                                                              13(22.0)                                                               0.319
  Body mass index (kg/m^2^)       19.6(18.6,20.5)^b^      19.7(18.6,20.5)^b^                                                    19.4(18.6,20.6)^b^                                                     0.536
  **Respiratory comorbidities**                                                                                                                                                                        
  Prior TB/NTM^c^                 127(52.0)               92(49.7)                                                              35(59.3)                                                               0.199
  Bronchiectasis                  208(85.2)               154(83.2)                                                             54(91.5)                                                               0.118
  COPD^c^                         16(6.6)                 13(7.0)                                                               3(5.1)                                                                 0.768
  Cor pulmonale                   12(4.9)                 10(5.4)                                                               2(3.4)                                                                 0.736
  Asthma                          15(6.1)                 12(6.5)                                                               3(5.1)                                                                 1.000
  **Main respiratory symptoms**                                                                                                                                                                        
  Cough                           201(82.4)               153(87.4)                                                             48(81.4)                                                               0.246
  Sputum                          206(84.4)               158(85.4)                                                             48(81.4)                                                               0.455
  Hemoptysis                      59(24.2)                47(25.4)                                                              12(20.3)                                                               0.429
  Shortness of breath             75(30.7)                54(29.2)                                                              21(35.6)                                                               0.353
  Chest pain                      48(19.7)                38(20.5)                                                              10(16.9)                                                               0.546
  **Radiographic features**                                                                                                                                                                            **\<0.001**
  Fibrocavitary                   61(25.0)                57(30.8)                                                              4(6.8)                                                                 
  Nodular bronchiectatic          171(70.1)               116(62.7)                                                             55(93.2)                                                               
  Indeterminate                   12(4.9)                 12(6.5)                                                               0(0)                                                                   

a

Data are the medians (interquartile range) or numbers (percentage).

b

Range.

c

TB, tuberculosis; NTM, non-tuberculous mycobacterium; COPD, chronic obstructive pulmonary disease.

Treatment Outcomes and Modalities {#S3.SS2}
---------------------------------

Only 45.1% of total patients (110/244) met the criteria for treatment success ([Table 2](#T2){ref-type="table"}). Significantly greater success was observed among patients infected with *M. abscessus* subsp. *massiliense* \[81.4% (48/59)\] compared to those infected with subsp. *abscessus* \[33.5% (62/185)\]. Clarithromycin used in drug regiments to treat patients infected with *M. abscessus* subsp. *abscessus* was more commonly associated with treatment failure than treatment success (85.4 vs. 71.0%, respectively). Treatments that included a different macrolide (azithromycin), on the other hand, achieved significantly greater success (37.1%) than failure (19.5%). These differences were not found upon analysis of the entire study population or patients infected with *M. abscessus* subsp. *massiliense*. Treatment with drug combinations that included amikacin, imipenem, linezolid, or tigecycline also exhibited far greater success than failure in treating the entire patient population, as well as treating those patients infected with *M. abscessus* subsp. *abscessus*. Drug combinations that included these same four antibiotics did not exert the same beneficial effects on patients infected with *M. abscessus* subsp. *massiliense*.

###### 

Comparison of treatment modalities: success versus failure^*a*^.

  **Antibiotic**                     ***M. abscessus* pulmonary disease**   ***M. abscessus* subsp. *abscessus* pulmonary disease**   ***M. abscessus* subsp. *massiliense* pulmonary disease**                                                                                                                         
  ---------------------------------- -------------------------------------- --------------------------------------------------------- ----------------------------------------------------------- --------- ------------------- -------------- -------------- ------- ------------------- -------------- -------------- -------
  Clarithromycin                     199                                    86(78.2)                                                  113(84.3)                                                   0.218     149                 44(71.0)       105(85.4)      0.020   50                  42(87.5)       8(72.7)        0.347
  Azithromycin                       61                                     32(29.1)                                                  29(21.6)                                                    0.181     47                  23(37.1)       24(19.5)       0.010   14                  9(18.8)        5(45.5)        0.110
  Amikacin                           218                                    104(94.5)                                                 114(85.1)                                                   0.017     166                 60(96.8)       106(86.2)      0.025   52                  44(91.7)       8(72.7)        0.112
  Imipenem                           67                                     39(35.5)                                                  28(20.9)                                                    0.011     47                  22(35.5)       25(20.3)       0.025   20                  17(35.4)       3(27.3)        0.734
  Meropenem                          13                                     7(6.4)                                                    6(4.5)                                                      0.514     10                  5(8.1)         5(4.1)         0.256   3                   2(4.2)         1(9.1)         0.468
  Cefoxitin                          144                                    65(59.1)                                                  79(59.0)                                                    0.983     110                 38(61.3)       72(58.5)       0.719   34                  27(56.2)       7(63.6)        0.745
  Linezolid^b^                       38                                     24(21.8)                                                  14(10.4)                                                    0.015     27                  15(24.2)       12(9.8)        0.009   11                  9(18.8)        2(18.2)        1.000
  Tigecycline                        53                                     32(29.1)                                                  21(15.7)                                                    0.011     39                  19(30.6)       20(16.3)       0.024   14                  13(27.1)       1(9.1)         0.269
  Doxycycline                        30                                     10(9.1)                                                   20(14.9)                                                    0.167     23                  6(9.7)         17(13.8)       0.420   7                   4(8.3)         3(27.3)        0.112
  Minocycline                        22                                     10(9.1)                                                   12(9.0)                                                     0.971     15                  4(6.5)         11(8.9)        0.558   7                   6(12.5)        1(9.1)         1.000
  Moxifloxacin^b^                    53                                     28(25.5)                                                  25(18.7)                                                    0.200     34                  13(21.0)       21(17.1)       0.519   19                  15(31.2)       4(36.4)        0.734
  Levofloxacin^b^                    26                                     8(7.3)                                                    18(13.4)                                                    0.121     20                  4(6.5)         16(13.0)       0.175   6                   4(8.3)         2(18.2)        0.310
  Ciprofloxacin                      17                                     8(7.3)                                                    9(6.7)                                                      0.865     13                  4(6.5)         9(7.3)         1.000   4                   4(8.3)         0(0)           1.000
  Number of patients administered:   --                                     --                                                        --                                                          0.810     --                  --             --             0.148   --                  --             --             0.367
  One parenteral drug                15                                     6(5.5)                                                    9(6.7)                                                      --        9                   1(1.6)         8(6.5)         --      6                   5(10.4)        1(9.1)         --
  Two parenteral drugs               161                                    70(63.6)                                                  91(67.9)                                                    --        124                 38(61.3)       86(69.9)       --      37                  32(66.7)       5(45.5)        --
  Three parenteral drugs             62                                     31(28.2)                                                  31(23.1)                                                    --        47                  21(33.9)       26(21.1)       --      15                  10(20.8)       5(45.5)        --
  More than three parenteral drugs   6                                      3(2.7)                                                    3(2.2)                                                      --        5                   2(3.2)         3(2.4)         --      1                   1(2.1)         0(0)           --
  Months of treatment                25.6 (18.8, 37.8)                      20.7                                                      30.0                                                        \<0.001   27.7 (20.7, 40.8)   23.4           30.0           0.001   20.2 (15.9, 29.8)   18.0           28.0           0.179
                                                                            (16.2, 31.0)                                              (22.0, 43.3)                                                                              (18.1, 34.6)   (22.0, 44.0)                               (15.9, 26.8)   (16.0, 43.0)   
  Surgical resection                 10                                     2                                                         8                                                           0.192     7                   1              6              0.427   3                   1              2              0.086

a

Data are the number (percentage; the number of patients who succeeded or failed treatment with the indicated drug divided by the total number of patients who succeeded or failed treatment) or median (interquartile range) of cases. Each antibiotic listed was included regardless of whether it was discontinued during the course of treatment.

b

Administered orally and/or intravenously.

The duration of treatment was significantly shorter for the total population of patient who were successfully treated versus patients who failed treatment. Similarly, the treatment duration was substantially shorter for *M. abscessus* subsp. *abscessus* infected patients who were successfully treated. Successfully treated patients infected with *M. abscessus* subsp. *massiliense* exhibited the same trend, but failed to achieve statistical significance. Efficacy of treatment modalities with respect to symptomatic and raidiographic improvement has also been made and similar outcome profiles are obtained ([Supplementary Tables 1, 2](#SM1){ref-type="supplementary-material"}).

Effects of Individual Drugs on Treatment Outcomes {#S3.SS3}
-------------------------------------------------

Multiple logistic regression analysis (adjusted for age, gender, BMI, and radiographic findings) indicated that azithromycin was clinically superior to clarithromycin in treating patients infected with *M. abscessus* subsp. *abscessus* ([Table 3](#T3){ref-type="table"}). The superiority of azithromycin was not observed in treating the total patient population or patients infected with *M. abscessus* subsp. *massiliense*. Amikacin, imipenem, linezolid, and tigecycline were also associated with success in treating the entire patient population, as well as those patients infected with *M. abscessus* subsp. *abscessus*. Notably, amikacin was the only drug showing clinical efficacy in treating *M. abscessus* subsp. *massiliense* infected patients in our study. The association of each drug with symptomatic and radiographic improvements was also subjected to multivariable logistic regression analysis ([Supplementary Tables 3, 4](#SM1){ref-type="supplementary-material"}).

###### 

Treatment success with individual antibiotics.

  **Antibiotic**    **Total (*n* = 244)**   ***M. abscessus* subsp. *abscessus* pulmonary disease (*n* = 185)**   ***M. abscessus* subsp. *massiliense* pulmonary disease (*n* = 59)**                                                             
  ----------------- ----------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------- ------- --------------- ------- -------- ---------------- -------
  Clarithromycin    0.588                   0.290--1.194                                                          0.142                                                                  0.425   0.191--0.945    0.036   1.460    0.214--9.962     0.699
  Azithromycin      1.558                   0.844--2.877                                                          0.156                                                                  2.339   1.141--4.794    0.020   0.295    0.061--1.418     0.128
  Amikacin          3.275                   1.221--8.788                                                          0.018                                                                  5.911   1.247--28.012   0.025   15.023   1.294--174.400   0.030
  Imipenem          2.078                   1.151--3.753                                                          0.015                                                                  2.050   1.018--4.126    0.044   1.357    0.280--6.575     0.705
  Meropenem         1.218                   0.390--3.806                                                          0.735                                                                  1.787   0.486--6.574    0.382   0.341    0.026--4.487     0.413
  Cefoxitin         1.121                   0.659--1.908                                                          0.672                                                                  1.253   0.656--2.394    0.495   0.610    0.133--2.795     0.524
  Linezolid^c^      2.231                   1.078--4.616                                                          0.031                                                                  2.875   1.221--6.772    0.016   1.286    0.189--8.746     0.797
  Tigecycline       2.040                   1.079--3.857                                                          0.028                                                                  1.971   0.931--4.173    0.076   2.614    0.291--23.514    0.391
  Doxycycline       0.599                   0.260--1.380                                                          0.229                                                                  0.628   0.222--1.772    0.379   0.408    0.053--3.147     0.390
  Minocycline       0.992                   0.399--2.467                                                          0.986                                                                  0.691   0.206--2.315    0.549   1.312    0.116--14.876    0.827
  Moxifloxacin^c^   0.695                   0.372--1.300                                                          0.255                                                                  0.866   0.393--1.908    0.720   1.495    0.303--7.388     0.622
  Levofloxacin^c^   0.474                   0.193--1.162                                                          0.103                                                                  0.453   0.142--1.445    0.181   0.242    0.032--1.857     0.172
  Ciprofloxacin     1.026                   0.372--2.831                                                          0.960                                                                  1.155   0.330--4.039    0.822   0        0                0

a

OR, odds ratio; CI, confidence interval.

b

Adjusted for age, sex, body mass index, and radiographic findings.

c

Administered orally and/or intravenously.

Adverse Effects of Antibiotics {#S3.SS4}
------------------------------

One hundred and ninety-two of the 244 patients enrolled in the study experienced 319 adverse events caused by therapeutic intervention ([Table 4](#T4){ref-type="table"}). The most frequent adverse events were gastrointestinal complaints that included nausea, vomiting, diarrhea, and abdominal pain. Hematologic toxicity and nephrotoxicity were the next most frequent events documented. Most of these were mild, tolerable, and did not result in disability or death. Serious adverse reactions, however, occurred in 60 (24.6%) patients resulting in a discontinuation or modification of the treatment regimen. Notably, severe myelosuppression was mainly a consequence of linezolid treatment. Gastrointestinal side effects were most often due to tigecycline; amikacin caused most cases of serious ototoxicity and nephrotoxicity. Fortunately, all severe side effects disappeared or were remarkably alleviated after changes in the treatment regimen.

###### 

Adverse events^∗^.

                                                     **Antibiotic-specific adverse events leading to treatment modification (*n* = 60)**                    
  --------------------------- ---------- ----------- ------------------------------------------------------------------------------------- --- ---- --- --- ----
  Gastrointestinal distress   79(41.1)   143(44.8)   4                                                                                     3   4    0   4   14
   Diarrhea                   15(7.8)    22(6.9)     0                                                                                     0   0    0   0   0
   Abdominal pain             13(6.8)    25(7.8)     1                                                                                     1   0    0   1   0
   Nausea                     35(18.2)   66(20.7)    1                                                                                     2   4    0   2   10
   Vomiting                   16(8.3)    30(9.4)     2                                                                                     0   0    0   1   4
  Dizziness                   7(2.9)     15(4.7)     0                                                                                     0   0    0   0   0
  Ototoxicity                 11(5.7)    15(4.7)     0                                                                                     0   14   0   0   0
  Nephrotoxicity              20(10.4)   34(10.7)    0                                                                                     0   5    0   0   0
  Hepatotoxicity              9(4.7)     15(4.7)     0                                                                                     0   0    0   0   1
  Hematologic toxicity        11(5.7)    26(8.2)     0                                                                                     0   0    1   5   0
  Leukopenia                  5(2.6)     11(3.4)     0                                                                                     0   0    1   2   0
  Thrombocytopenia            2(1.0)     5(1.6)      0                                                                                     0   0    0   2   0
  Anemia                      4(2.1)     10(3.13)    0                                                                                     0   0    0   1   0
  Insomnia                    3(1.6)     6(1.9)      0                                                                                     0   0    0   0   0
  Fever                       3(1.6)     5(1.6)      0                                                                                     0   0    0   0   0
  Headache                    14(7.3)    22(6.9)     0                                                                                     0   0    0   0   0
  Myoclonus                   3(1.6)     4(1.3)      0                                                                                     0   0    0   0   0
  Agitation                   3(1.6)     3(0.9)      0                                                                                     0   0    1   0   0
  Taste alteration            10(5.2)    11(3.4)     0                                                                                     0   0    0   0   0
  Allergic reactions          19(9.9)    20(6.3)     0                                                                                     0   3    1   0   0

∗

The patients affected by the adverse event listed are enumerated. Notably, a single patient is often affected by more than one event. Those antibiotics, which most frequently cause events that necessitates treatment modification, are listed.

Discussion {#S4}
==========

The study reported here evaluated the efficacy and adverse effects of different antibiotics used in combination to treat patients with pulmonary disease caused by *M. abscessus*. A variety of antibiotics recommended by the British Thoracic Society guidelines were analyzed including linezolid and tigecycline, two important drugs recently used more frequently. While the overall rate of treatment success remained very low, the incorporation of amikacin, imipenem, linezolid, and/or tigecycline into treatment regimens was associated with increased success. The overall safety of macrolide-based regimens was moderately satisfactory since no fatalities or disabilities resulted from treatment. However, the total incidence of adverse effects was high. Indeed, there were cases in which patients were unable to tolerate one or more potentially effective drugs, i.e., azithromycin, amikacin, imipenem, linezolid, and tigecycline, during the course of treatment.

Two recent meta-analyses reported disappointing treatment outcomes for *M. abscessus* pulmonary disease. The therapeutic efficiency rates were 54 and 45.6% for all patients, and 35 and 33.0% for patients diagnosed with pulmonary, *M. abscessus* subsp. *abscessus* infections ([@B28]; [@B13]). Similar rates of treatment success are reported here, i.e., 45.1% for all cases of *M. abscessus* pulmonary disease and 33.5% for cases involving *M. abscessus* subsp. *abscessus*. As such, the therapeutic efficacy of *M. abscessus* pulmonary disease continues to be unsatisfactory, and is even worse for *M. abscessus* subsp. *abscessus* infections.

Amikacin exhibits a high level of antibacterial activity and a low rate of resistance *in vitro*; its successful use to treat pulmonary, *M. abscessus* infections has been reported ([@B27]; [@B16]). Indeed, amikacin administered parenterally is regarded as one of the most active antibiotics available to treat *M. abscessus* pulmonary disease ([@B4]). Consistent with this perception, amikacin administered in our study was strongly associated with the alleviation of symptoms and treatment success suggesting that amikacin remains an ideal, first choice for treating *M. abscessus* infections. Clinicians should be aware, however, that amikacin is ototoxic. As such, blood concentration of amikacin should be monitored continually to ensure safety.

The anti-*M. abscessus* activity of imipenem *in vitro* is variable; bacterial resistance was over 60% in some studies ([@B2]; [@B17]; [@B19]). Imipenem was efficacious, however, in treating pulmonary *M. abscessus* disease in our study. Similar results were reported by [@B13]. The elevated antimicrobial activity expressed by imipenem intracellularly provides one plausible explanation for the apparent difference in activity exhibited *in vitro* versus *in vivo* ([@B29]). In this regard, the high *in vivo* killing activity of imipenem in an embryonic zebrafish test system was reported ([@B18]). Moreover, it is likely that the combination of imipenem with other antibiotics has a synergistic or additive effect, which contributes to the treatment success associated with imipenem ([@B23]; [@B14]). Notably, imipenem caused the fewest severe, adverse side effects among the four dominant drugs (i.e., amikacin, imipenem, linezolid, and tigecycline) identified in this study suggesting that it should be included as a treatment option provided *in vitro* sensitivity testing demonstrates the susceptibility of the clinical *M. abscessus* isolate. Furthermore, a newly developed beta-lactamase inhibitor, relebactam, has been shown to significantly improve the anti-*M. abscessus* activity of imipenem *in vitro* and no additional consideration needed to be addressed when imipenem and relebactam are used together ([@B34]; [@B11]).

Accumulated evidence suggests that linezolid possesses elevated anti-*M. abscessus* activity. Recently, we reported the high activity expressed by linezolid *in vitro* against clinical *M. abscessus* isolates collected from patients with lung diseases ([@B33]). A study conducted using a *Drosophila melanogaster*-infection model demonstrated the anti-*M. abscessus* activity of linezolid *in vivo* ([@B26]); the successful use of linezolid in treating clinical *M. abscessus* infections was also reported ([@B10]). These results are supported by data presented here. Better outcomes occurred when linezolid was a component of multi-drug therapy used to treat *M. abscessus* pulmonary disease. Linezolid has the advantage that it can be administered orally. It penetrates well into both extracellular fluid and cells, making linezolid one of the more important options for treating *M. abscessus* infections ([@B9]). Linezolid-induced myelosuppression, however, was the most severe event leading to treatment intervention in our study. Considering its high price and limited availability in some areas, linezolid may be a more appropriate secondary treatment choice, especially when antibiotic sensitivity testing demonstrates alternatives.

Tigecycline exhibits the potentially strongest antibacterial activity of any antibiotic against *M. abscessus in vitro*. One study conducted in Japan showed it exerts 100% bacteriostasis against *M. abscessus* at very low concentrations (MIC ≤ 0.5 μg/ml), which is far superior to the antibacterial effect of clarithromycin (62%) and linezolid (77%) at the CLSI recommended breakpoint ([@B6]). Similar results were found in both France (90%, MIC ≤ 1 μg/ml) and China (94.3%, MIC ≤ 2 μg/ml) ([@B24]; [@B20]). Moreover, the combination of tigecycline with clarithromycin *in vitro* produces synergistic antibacterial effects against *M. abscessus* ([@B35]). Tigecycline also showed excellent therapeutic effects against *M. abscessus* infection in a clinical study. [@B32] reported that daily treatment of *M. abscessus* disease with 50--100 mg tigecycline for 1 month resulted in a clinical remission rate that exceeded 60%. Tigecycline also proved superior in treating *M. abscessus* infections in the study reported here, supporting the British Thoracic Society guidelines that list tigecycline as a first-line solution for treating *M. abscessus* infections ([@B7]). It is pertinent to note that tigecycline-treated patients often suffered from severe nausea and vomiting. Notably, two newly developed tetracycline analogs, omadacycline and eravacycline, have been reported to show therapeutic potential in treatment of *M. abscessus* infection ([@B12]; [@B30]), with similar *in vitro* activity to tigecycline, but better tolerated.

The study described herein has several limitations. First, it is a retrospective analysis of data obtained at a single center, which could limit the generalization and accuracy of the results. Second, only a relatively small number of *M. abscessus* subsp. *massiliense* infected cases were included, consequently, their characteristics may not be well representative. Third, due to the simultaneous administration of multiple antibiotics, conclusions regarding the adverse effects of individual drugs may be inaccurate. Four, this study excluded subjects who failed to complete their follow-up visits. Conceivably, this failure occurs as a consequence of adverse drug side effects resulting in an underestimation of the adverse events that could otherwise lead to treatment modification. Finally, antibiotics are selected strictly according to guidelines or sputum culture results in our study, rather than at random, resulting in the occurrence of prescription bias. However, it is inevitable.

Conclusion {#S5}
==========

The success rate of *M. abscessus* pulmonary disease treatment is still unsatisfactory, albeit the use of amikacin, imipenem, linezolid, and tigecycline is associated with increased treatment success. Adverse effects are common due to the long-term combination anti-*M. abscessus* therapy. Ototoxicity caused by amikacin, gastrointestinal side effects caused primarily by tigecycline, and myelosuppression caused by linezolid were the most severe adverse effects observed.
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